Belite Bio Inc - Adr (BLTE)

$38

+0.73

(+1.96%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Belite Bio Inc - Adr

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.9% return, outperforming this stock by 26.4%

Performance

  • $36.01
    $38.49
    $38.00
    downward going graph

    5.24%

    Downside

    Day's Volatility :6.44%

    Upside

    1.27%

    downward going graph
  • $11.00
    $48.60
    $38.00
    downward going graph

    71.05%

    Downside

    52 Weeks Volatility :77.37%

    Upside

    21.81%

    downward going graph

Returns

PeriodBelite Bio Inc - AdrSector (Health Care)Index (Russel 2000)
3 Months
-18.96%
1.1%
0.0%
6 Months
0.4%
12.5%
0.0%
1 Year
24.77%
6.9%
2.2%
3 Years
154.4%
14.3%
-23.0%

Highlights

Market Capitalization
1.1B
Book Value
$3.1
Earnings Per Share (EPS)
-1.19
Wall Street Target Price
56.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-28.5%
Return On Equity TTM
-47.95%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-31.5M
Diluted Eps TTM
-1.19
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.77
EPS Estimate Next Year
-0.82
EPS Estimate Current Quarter
-0.3
EPS Estimate Next Quarter
-0.25

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Belite Bio Inc - Adr(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 48.68%

Current $38.00
Target $56.50

Technicals Summary

Sell

Neutral

Buy

Belite Bio Inc - Adr is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Belite Bio Inc - Adr
Belite Bio Inc - Adr
-14.81%
0.4%
24.77%
154.4%
154.4%
Moderna, Inc.
Moderna, Inc.
1.34%
41.81%
-16.73%
-38.71%
314.51%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Belite Bio Inc - Adr
Belite Bio Inc - Adr
NA
NA
NA
-0.77
-0.48
-0.28
NA
3.1
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Belite Bio Inc - Adr
Belite Bio Inc - Adr
Buy
$1.1B
154.4%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
314.51%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • Armistice Capital, LLC

    0.12%

  • Morgan Stanley - Brokerage Accounts

    0.08%

  • State Street Corporation

    0.06%

  • Cubist Systematic Strategies, LLC

    0.06%

  • Marshall Wace Asset Management Ltd

    0.05%

  • JPMorgan Chase & Co

    0.05%

Company Information

belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.

Organization
Belite Bio Inc - Adr
Employees
20
CEO
Dr. Yu-Hsin Lin M.B.A., Ph.D.
Industry
Healthcare

Discover More

FAQs